Evidence map›Paper›PMID 34223152›Full record

ArticleJAC-antimicrobial resistance2021

Compassionate use of cefiderocol for carbapenem-resistant

Diana A Mabayoje, Caoimhe NicFhogartaigh, Benny P Cherian, Mei Gie Meiqi Tan, David W Wareham

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JAC-antimicrobial resistance, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Treatment of infections caused by carbapenem-resistantFrontiers in cellular and infection microbiology · 2024
    Review
  4. Article
  5. Review
  6. Carbapenem-ResistantOpen forum infectious diseases · 2023
    Article
  7. Article
  8. Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2023
    Review
  9. Update on the Management of Surgical Site Infections.Antibiotics (Basel, Switzerland) · 2022
    Review
  10. Observational
  11. Review
  12. Review
  13. JAC-antimicrobial resistance · 2021
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Diana A MabayojeDivision of Infection, Barts Health NHS Trust, London, UK.
Caoimhe NicFhogartaighDivision of Infection, Barts Health NHS Trust, London, UK.
Benny P CherianDivision of Infection, Barts Health NHS Trust, London, UK.
Mei Gie Meiqi TanAntimicrobial Research Group, Blizard Institute, Queen Mary University of London, London, UK.
David W WarehamDivision of Infection, Barts Health NHS Trust, London, UK.ORCID https://orcid.org/0000-0003-4331-5224
Barts Health NHS Trust · GBQueen Mary University of London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCefiderocol is a recently licensed novel siderophore-conjugated cephalosporin stable to hydrolysis by serine and MBLs. It has been successfully used to treat Enterobacterales infections and is approved for the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options.

objectivesTo describe the compassionate use of cefiderocol and clinical outcome in a case of prosthetic joint infection due to MDR PATIENTS AND

methodsThis case study follows a 66-year-old woman who sustained an open fracture of the left distal humerus in Pakistan. She underwent open reduction and internal fixation and on return to the UK presented to hospital with a discharging surgical wound.

resultsDebridement of her wound cultured NDM carbapenemase-producing

conclusionsCefiderocol's novel mode of cell entry is effective against MDR Gram-negative bacteria with reduced toxicity compared with other last line antibiotics. Our case demonstrates that cefiderocol may be useful as therapy for patients with limited treatment options due to antimicrobial resistance.

Identifiers

PMID34223152
PMCPMC8251250
OpenAlexW3176499846

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.